On Mar. 24, 2020, Windtree Therapeutics announced it will study its proprietary KL4 surfactant to potentially mitigate the pulmonary effects of severe COVID-19 infection. The Company is actively pursuing several non-dilutive opportunities to fund this project, including government agencies and private foundations.

Windtree’s proprietary synthetic, peptide-containing KL4 surfactant is similar to human surfactant and has been approved by the FDA in a previous liquid dose formulation for RDS in premature infants. Windtree has also developed an innovative Aerosol Delivery System which, in combination with KL4 surfactant, is being studied for non-invasive treatment of RDS.